The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Hualan Biological Bacterin Inc., a subsidiary company of one of China’s leading biopharmaceutical producers and the largest influenza vaccine manufacturer, Hualan Biological Engineering Inc., have entered an agreement to produce over 100 million doses per year of the Sputnik V vaccine in China.   This amount of the vaccine will be sufficient to vaccinate over 50 million people, according to RDIF. To date Sputnik V has...